Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512, a Novel Topical Drug Candidate for Dry Eye
AR-15512, a topical transient receptor potential melastatin 8 (TRPM8) agonist, is a first-in-class product candidate for the treatment of the signs and symptoms of dry eye disease. In both pivotal efficacy and safety studies (COMET-2 and COMET-3), the primary endpoint was achieved (p <0.0001)
Clinical Trial Information about COMET-4, found here.
AR-15512 is an investigational drug product that has not been submitted to the U.S. Food and Drug Administration (FDA) for approval and is not currently commercially available.
![](/sites/g/files/rbvwei1736/files/styles/535x400/public/2024-03/GettyImages-576919878.jpg?itok=sN8vaAUM)
AR-15512 Timeline
COMET: Clinical Development Program for AR-15512
![](/sites/g/files/rbvwei1736/files/styles/535x400/public/2024-03/Photo463.jpg?itok=MckaDst2)
Pipeline Focus
We continue to build our pharmaceutical pipeline focusing on promising and large categories.
![](/sites/g/files/rbvwei1736/files/styles/535x400/public/2024-03/GettyImages-1027139762.jpg?itok=tYlY1mUt)